首页 / 院系成果 / 成果详情页

CDK6 axis sensitizes AKT inhibition in luminal breast cancer 期刊论文

编号：

490f3c3f-b930-4543-8a00-412059175a57
作者：

Liu, Jingyi#^[1,2,3]Duan, Zhibing^[1,2];Guo, Weijie^[1,2];Zeng, Lei(曾雷)^[4,5]Wu, Yadi^[2,6];Chen, Yule^[1,2];Tai, Fang^[7,8,9];Wang, Yifan^[1,2];Lin, Yiwei^[1,2];Zhang, Qiang(张强)^[4,5]He, Yanling^[7,8,9];Deng, Jiong^[10];Stewart, Rachel L.^[2];Wang, Chi^[2];Lin, Pengnian Charles^[3];Ghaffari, Saghi^[11];Evers, B. Mark^[2,12];Liu, Suling(柳素玲)*^[13]Zhou, MingMing*^[4]Zhou, Binhua P.*^[1,2]Shi, Jian(石坚)*^[1,2,7,8,9]
语种：

English
期刊：

NATURE COMMUNICATIONS ISSN：2041-1723 2018 年 9 卷 ; DEC 5
收录：
摘要：

BRD4 assembles transcriptional machinery at gene super-enhancer regions and governs the expression of genes that are critical for cancer progression. However, it remains unclear whether BRD4-mediated gene transcription is required for tumor cells to develop drug resistance. Our data show that prolonged treatment of luminal breast cancer cells with AKT inhibitors induces FOXO3a dephosphorylation, nuclear translocation, and disrupts its association with SirT6, eventually leading to FOXO3a acetylation as well as BRD4 recognition. Acetylated FOXO3a recognizes the BD2 domain of BRD4, recruits the BRD4/RNAPII complex to the CDK6 gene promoter, and induces its transcription. Pharmacological inhibition of either BRD4/FOXO3a association or CDK6 significantly overcomes the resistance of luminal breast cancer cells to AKT inhibitors in vitro and in vivo. Our study reports the involvement of BRD4/FOXO3a/CDK6 axis in AKTi resistance and provides potential therapeutic strategies for treating resistant breast cancer.
推荐引用方式
GB/T 7714：

Liu Jingyi,Duan Zhibing,Guo Weijie, et al. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer [J].NATURE COMMUNICATIONS,2018,9.
APA：

Liu Jingyi,Duan Zhibing,Guo Weijie,Zeng Lei,&Shi Jian.(2018).Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer .NATURE COMMUNICATIONS,9.
MLA：

Liu Jingyi, et al. "Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer" .NATURE COMMUNICATIONS 9(2018).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：90  下载次数：0

分享到：

浏览次数：90

下载次数：0

打印次数：0